Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT02979561

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02979561
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02979561. Randomized; no masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2018-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
Acronym
Re-Spire
Condition
Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy
Intervention (Drug)
Dabigatran Etexilate
Intervention (Drug)
Warfarin
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation (class: research network)

Record details

Record id
cardio:ct-nct02979561
Content hash
a01fa7cdbc93d5b55a42fb126c733c643bf58876cd8481f9072ed391a893e197